Atypical Antipsychotics and the Risk of Diabetes in an Elderly Population in Long-Term Care: A Retrospective Nursing Home Chart Review Study

Journal of the American Medical Directors Association

Volumn 10, Issue 2, 2009, Pages 115-119

  Albert, Stewart G ^a   Grossberg, George T ^a   Thaipisuttikul, Papan J ^a   Scouby, Jarod ^b   Green, Erin ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

Atypical antipsychotic agents; diabetes mellitus; elderly; nursing home

Indexed keywords

ANTIDIABETIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; DONEPEZIL; GALANTAMINE; GLUCOSE; MEMANTINE; NOOTROPIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; ZIPRASIDONE;

AGED; ALZHEIMER DISEASE; ANXIETY DISORDER; ARTICLE; BODY MASS; COMMUNITY; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DIET RESTRICTION; DIET THERAPY; DISEASE EXACERBATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NURSING HOME; OBESITY; POPULATION RESEARCH; PRESCRIPTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCREENING; WEIGHT GAIN;

EID: 58849099487     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2008.08.005     Document Type: Article

References (14)

1. Sink K.M., Holden K.F., and Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. A Review of the Evidence JAMA 293 (2005) 596-608
2. Schneider L.S., Dagerman K.S., and Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. Meta-analysis of randomized placebo-controlled trials. JAMA 294 (2005) 1934-1943
3. Wang P.S., Schneeweis S., Avorn J., et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Eng J Med 353 (2005) 2335-2341
4. Schneider L.S., Tariot P.N., Lyketsos C.G., et al. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Alzheimer Disease Trial Methodology. Am J Geriatr Psychiatry 9 (2001) 346-360
5. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologist, and North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care 27 (2004) 596-601
6. Gianfrancesco F.D., Grogg A.L., Mahmoud R.A., et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: Findings from a large health plan database. J Clin Psychiatry 63 (2002) 920-930
7. Buse J.B., Cavazzoni P., Hornbuckle K., et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 56 (2003) 164-170
8. Leslie D.L., and Rosenheck R.A. Incidence of newly diagnosed diabetes attributable to atypical antipsyhcotic medications. Am J Psychiatry 161 (2004) 1709-1711
9. Newcomer J.W. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 65 suppl (2004) 36-46
10. Ader M., Kim S.P., Catalano K.J., et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 54 (2005) 862-871
11. Henderson D.C., Cagliero E., Copeland P.M., et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 62 (2005) 19-28
12. Schneider L.S., Tariot P.N., Dagerman K.S., et al., CATIE-AD study group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Eng J Med 355 (2006) 1525-1538
13. Colton T. Longitudinal studies and the use of the life table. Statistics in Medicine (1974), Little Brown and Co, Boston 237-250
14. Kenney S.J., Aubert R.E., and Geiss L.S. Prevalence and incidence of non-insulin-dependent diabetes mellitus. In: Harris M.I., Cowie C.C., Stern M.P., et al. (Eds). Diabetes in America. 2nd edition (1995), National Institutes of Health, Bethesda, MD 47-68